Abstract P300: Circulating MicroRNAs Associated with Glycemic Impairment and Progression in Asian Indians
Introduction: Asian Indians experience a high incidence of type 2 diabetes (T2D), but factors associated with glycemic progression from normal to pre-diabetes to diabetes in this population are not fully understood. Circulating microRNAs (miRs) appear to be implicated in T2D etiology in other racial groups.
Hypothesis: Circulating miRs are associated with glycemic impairment and progression in participants in the Metabolic Syndrome and Atherosclerosis in South Asians Living in America (MASALA) study.
Methods: Participants were 128 Asian Indians age 45-84 years without cardiovascular disease and not taking diabetes medications. Oral glucose tolerance tests were performed at baseline and after 2.5 years. Glycemic progression was defined as (1) progression from normal to impaired fasting glucose (fasting glucose 100-125 mg/dl) or diabetes (2-hour glucose ≥200 mg/dl, fasting glucose ≥126 mg/dl or diabetes medication use) or (2) from impaired glucose tolerance (2-hour glucose 140-199 mg/dl) to diabetes (see above). Circulating miRs from plasma collected during the enrollment visit were measured using the Firefly Circulating microRNA assay. Unadjusted and multivariate-adjusted logistic regression models were created to determine the relationship between circulating miRs and glycemic impairment and progression.
Results: The mean age was 57 ± 8 years and 48% (n=62) were men. Glycemic impairment was present in 57% (n=73) at baseline. The prevalence of glycemic progression after 2.5 years was 24% (n=23). Two circulating miRs were associated with glycemic impairment and seven with glycemic progression after 2.5 years (see Table).
Conclusions: To our knowledge, this is the first study to investigate circulating miRs associated with glycemic impairment in the high risk Asian Indian racial group. Individual miRs were significantly associated with both glycemic impairment and glycemic progression. Further studies are needed to determine whether miR(s) might be useful clinical biomarkers for incident T2D in this population.
Author Disclosures: E. Flowers: B. Research Grant; Modest; Firefly Bioworks, Inc.. B.E. Aouizerat: None. M. Gadgil: None. A.M. Kanaya: None.
- © 2015 by American Heart Association, Inc.